Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Illumina is making available three new product solutions for cancer research, which include expansion of the company's proprietary DASL Assay to whole-genome profiling, and the launch of DASL-focused expression and methylation profiling on VeraCode technology.
Subscribe to our email newsletter
These new solutions allow researchers to leverage synergies across Illumina technology platforms to better understand the complex molecular mechanisms that give rise to cancer. DASL Assay was specifically designed to successfully profile expression in degraded RNA, such as that found in formalin-fixed paraffin embedded (FFPE) samples.
Using the company’s GoldenGate Assay for Methylation with the VeraCode technology, researchers can now uncover epigenetic modifications in DNA that have significant and widespread effects on gene expression.
Tristan Orpin, senior vice president of Illumina’s commercial operations, said: “The DASL gene expression and GoldenGate Methylation assays offered across both the BeadArray and VeraCode facilitate the understanding of the molecular basis of cancer. Researchers will need to investigate changes in RNA expression, epigenetic control, and coding and non-coding regions of the genome. Illumina’s new solutions for RNA profiling and methylation will enable researchers to study and validate these changes with a common assay.”